Pfizer Chief Executive Officer Albert Bourla said the drugmaker is in “active discussions” with the highest levels of the U.S. government, including President Donald Trump, over policies aimed at lowering prescription-medicine costs. Bourla told investors on the company’s second-quarter earnings call that he has been in contact with the White House since a July 31 letter in which Trump demanded price cuts and threatened punitive measures if companies fail to act. Bourla added that Pfizer and other large pharmaceutical manufacturers are prepared to expand direct-to-consumer sales, one of four requirements outlined in Trump’s letter. The initiative is tied to a proposed Most Favored Nation rule that would peg U.S. prices to the lowest charged in other industrialized countries. Pfizer already offers several medicines through online and telehealth channels and recently partnered with Bristol Myers Squibb to provide the blood thinner Eliquis at a discounted cash price. The CEO also addressed the administration’s plan to impose sector-specific tariffs that could rise to as much as 250% on imported drugs, saying early conversations suggest a “small” levy and a grace period before any increase. Bourla indicated Pfizer can absorb this year’s tariff and pricing impacts while still meeting guidance, reaffirming 2025 revenue of $61 billion to $64 billion and lifting its adjusted diluted earnings-per-share forecast by $0.10.